- Viking Therapeutics (VKTX, Financial) reported a net loss of $45.6 million for Q1 2025, with cash reserves of $852 million.
- Phase 3 trials for the obesity treatment VK2735 are set to commence in Q2 2025.
- A new manufacturing agreement with CordenPharma secures future commercial production capabilities for VK2735.
Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company, announced its financial results for the first quarter of 2025, demonstrating significant financial developments and advancements in clinical trials. The company reported a net loss of $45.6 million ($0.41 per share), compared to a $27.4 million net loss in Q1 2024, primarily due to increased research and development expenses, which rose to $41.4 million from $24.1 million year-over-year.
The company ended the quarter with a robust cash position of $852 million, down from $903 million at the end of 2024. This financial cushion is projected to support the company's pipeline developments over the next four years.
One of the key highlights in Viking's pipeline is the progression towards Phase 3 trials for VK2735, a subcutaneous formulation for treating obesity, expected to begin in the second quarter of 2025. This follows promising results from the Phase 2 VENTURE study, which reported a statistically significant weight loss of up to 14.7% over 13 weeks.
In addition to pipeline developments, Viking solidified a comprehensive manufacturing partnership with CordenPharma. This agreement secures the production capacity for active pharmaceutical ingredients (APIs) and the filling/finishing capabilities necessary for both injectable and oral formulations of VK2735, indicating readiness for commercialization.
The company also fully enrolled its Phase 2 VENTURE-Oral Dosing trial, with results anticipated in the second half of 2025. These developments underscore Viking's focus on advancing its clinical programs to address metabolic and endocrine disorders.
